Liquidia Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting
30 September 2024 - 10:00PM
Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company
developing innovative therapies for patients with rare
cardiopulmonary diseases, announced today the company will
present a poster and host a medical theater at the CHEST 2024
annual meeting hosted by the American College of Chest Physicians
on October 6-9, 2024, in Boston.
Rajeev Saggar, MD, Chief Medical Officer at Liquidia, said:
“Every year, CHEST unites the next generation of medical
professionals and organizations responsible for advancing patient
care and educating the future leaders in our field. As such, we are
proud to be sharing insight regarding our ongoing ASCENT trial
evaluating the safety and tolerability of YUTREPIA™ (treprostinil)
inhalation powder in patients with pulmonary hypertension
associated with interstitial lung disease (PH-ILD).”
Liquidia’s poster, entitled “Baseline Characteristics of
Patients Enrolled in the ASCENT Study: Evaluating Safety and
Tolerability of YUTREPIA™, A Dry Powder Inhaled Treprostinil in
Pulmonary Hypertension Associated with Interstitial Lung Disease
(PH-ILD),” will be presented on Wednesday, October 9th, 2024, from
10:20 a.m. – 11:05 a.m. ET. The poster will focus on the company’s
ongoing clinical trial, dosing and tolerability profiles, and
exploratory efficacy endpoints for the use of YUTREPIA in PH-ILD
patients in the ASCENT trial. Upon presentation, the poster will be
available on Liquidia’s website at
https://liquidia.com/products-and-pipeline/publications.The
company’s medical theater, which will take place on October 7, 2024
from 12:15 p.m. to 1:00 p.m. ET and is open to all meeting
attendees, will focus on current epidemiologic data on PH-ILD, the
clinical data gap regarding dry-powder treprostinil use in PH-ILD
and how Liquidia’s ASCENT study is addressing this gap, as well as
the future of PH-ILD treatments. About YUTREPIA™
(treprostinil) Inhalation PowderYUTREPIA is an
investigational, inhaled dry-powder formulation of treprostinil
delivered through a convenient, low-effort, palm-sized device. The
FDA previously issued tentative approval of YUTREPIA for the PAH
indication in November 2021. In July
2023, Liquidia filed an amendment to its New Drug
Application for YUTREPIA, seeking to add PH-ILD to the label.
YUTREPIA was designed using Liquidia’s PRINT® technology,
which enables the development of drug particles that are precise
and uniform in size, shape and composition, and that are engineered
for enhanced deposition in the lung following oral
inhalation. Liquidia has completed INSPIRE, or
Investigation of the Safety and Pharmacology of Dry Powder
Inhalation of Treprostinil, an open-label, multi-center phase 3
clinical study of YUTREPIA in patients diagnosed with PAH who are
naïve to inhaled treprostinil or who are transitioning from
Tyvaso® (nebulized treprostinil). YUTREPIA is currently being
studied in the ASCENT trial, an Open-Label Prospective Multicenter
Study to Evaluate Safety and Tolerability of Dry Powder Inhaled
Treprostinil in Pulmonary Hypertension, with the objective of
informing YUTREPIA’s dosing and tolerability profile in patients
with PH-ILD. YUTREPIA was previously referred to as LIQ861 in
investigational studies.About Liquidia
CorporationLiquidia Corporation is a
biopharmaceutical company developing innovative therapies for
patients with rare cardiopulmonary disease. The company’s current
focus spans the development and commercialization of products in
pulmonary hypertension and other applications of its proprietary
PRINT® Technology. PRINT enabled the creation of Liquidia’s
lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an
investigational drug for the treatment of pulmonary arterial
hypertension (PAH) and pulmonary hypertension associated with
interstitial lung disease (PH-ILD). The company is also developing
L606, an investigational sustained-release formulation of
treprostinil administered twice-daily with a next-generation
nebulizer, and currently markets generic Treprostinil Injection for
the treatment of PAH. To learn more about Liquidia, please
visit www.liquidia.com.
Tyvaso® is a registered trademark of United Therapeutics
Corporation.Cautionary Statements Regarding Forward-Looking
Statements This press release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this press release other than statements of historical facts,
including statements regarding our future results of operations and
financial position, our strategic and financial initiatives, our
business strategy and plans and our objectives for future
operations, are forward-looking statements. Such forward-looking
statements, including statements regarding clinical trials,
clinical studies and other clinical work (including the funding
therefor, anticipated patient enrollment, safety data, study data,
trial outcomes, timing or associated costs), regulatory
applications and related submission contents and timelines, and our
ability to execute on our strategic or financial initiatives,
involve significant risks and uncertainties and actual results
could differ materially from those expressed or implied herein. The
words “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “target,” “would,” and similar expressions are
intended to identify forward-looking statements. We have based
these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our financial condition, results
of operations, business strategy, short-term and long-term business
operations and objectives and financial needs. These
forward-looking statements are subject to a number of risks
discussed in our filings with the SEC, as well as a number of
uncertainties and assumptions. Moreover, we operate in a very
competitive and rapidly changing environment and our industry has
inherent risks. New risks emerge from time to time. It is not
possible for our management to predict all risks, nor can we assess
the impact of all factors on our business or the extent to which
any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements we may make. In light of these risks, uncertainties and
assumptions, the future events discussed in this press release may
not occur and actual results could differ materially and adversely
from those anticipated or implied in the forward-looking
statements. Nothing in this press release should be regarded as a
representation by any person that these goals will be achieved, and
we undertake no duty to update our goals or to update or alter any
forward-looking statements, whether as a result of new information,
future events or otherwise. Contact
InformationInvestors:Jason Adair Chief
Business
Officer919.328.4350jason.adair@liquidia.comMedia:
Patrick WallaceDirector, Corporate
Communications919.328.4383patrick.wallace@liquidia.com
Liquidia (NASDAQ:LQDA)
Historical Stock Chart
From Oct 2024 to Nov 2024
Liquidia (NASDAQ:LQDA)
Historical Stock Chart
From Nov 2023 to Nov 2024